(P-711) Persistence of Immunogenicity and Safety of the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) Administered to Adults 50–59 Years of Age (YOA)

Colchester Research Group, Truro, Canada
Truro, Nova Scotia, Canada

Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany
Wuerzburg, Bayern, Germany

Centro Medico Maffei, Buenos Aires, Argentina
Buenos Aires, Buenos Aires, Argentina

Son Espases University Hospital, Palma de Mallorca, Mallorca, Balearic Islands, Spain
Mallorca, Islas Baleares, Spain

Clinical Agnieszka Mital Centrum Badan Clinic, Elblag, Poland
Warsaw, Mazowieckie, Poland

Vacunar, Sede Las Cañitas, Buenos Aires, Argentina
Buenos Aires, Buenos Aires, Argentina

Clinique de Pneumologie et du Sommeil de Lanaudière, Saint-Charles-Borromée, Québec, Canada
Saint-Charles-Borromée, Quebec, Canada

Studienzentrum Mainz Mitte, Mainz, Germany
Mainz, Rheinland-Pfalz, Germany

Praxis Dr. Med. Nicole Toursarkissian, Berlin, Germany
Berlin, Berlin, Germany

Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain
Madrid, Madrid, Spain

Praxis Dr. Med. Josef Großkopf, Wallerfing, Germany
Wallerfing, Bayern, Germany

QPS Netherlands B.V., Groningen, The Netherlands
Groningen, Groningen, Netherlands

Clinical Research Institute, Minneapolis, MN, USA
Minneapolis, Minnesota, United States

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

Expert Scientist
GSK
Wavre, Brabant Wallon, Belgium

Senior Scientist
GSK
Rixensart, Brabant Wallon, Belgium

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

Lead statistician
GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

GSK, Wavre, Belgium
Wavre, Vlaams-Brabant, Belgium

GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

Sr Clinical Science Lead
GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium

Sr Dir. Clinical Project Lead RSV OA
GSK, Wavre, Belgium
Wavre, Brabant Wallon, Belgium